Your browser doesn't support javascript.
loading
A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor.
Mumford, Lisa; Fuggle, Susan V; Martorell, Jaume; Slavcev, Antonij; Iniotaki, Aliki; Haasnoot, Geert W; Heidt, Sebastiaan; Claas, Frans H J.
Afiliación
  • Mumford L; Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, UK.
  • Fuggle SV; Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, UK; Oxford Transplant Centre, Nuffield Department of Surgical Sciences, University of Oxford, UK.
  • Martorell J; Hospital Clinic, Barcelona, Spain.
  • Slavcev A; Dept. Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Iniotaki A; National Tissue Typing Center, General Hospital of Athens "G. Gennimatas", Athens, Greece.
  • Haasnoot GW; Eurotransplant Reference Laboratory, Leiden University Medical Centre, Leiden, the Netherlands.
  • Heidt S; Eurotransplant Reference Laboratory, Leiden University Medical Centre, Leiden, the Netherlands.
  • Claas FHJ; Eurotransplant Reference Laboratory, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: fhjclaas@lumc.nl.
Transpl Immunol ; 64: 101354, 2021 02.
Article en En | MEDLINE | ID: mdl-33276060
ABSTRACT
Immunisation against Human Leucocyte Antigens (HLA) can be caused by pregnancy, blood transfusion, or organ transplants. The HLA antibody status of a given patient significantly influences their access and waiting time to transplant. For some highly sensitised patients (HSP) there is hardly any suitable donor available in the deceased donor pool of their allocation organisation and therefore they wait a very long time before being offered a kidney for transplant. Especially patients with rare HLA phenotypes in relation to the actual donor pool are waiting extremely long. As HLA phenotypes are different in the various European populations, we hypothesized that extension of the donor pool outside the respective allocation system will increase the chance of receiving a compatible transplant for this subgroup of highly sensitised patients. One of the objectives of the EUROSTAM project, (a Europe-wide Strategy to enhance Transplantation of highly sensitised patients on the basis of Acceptable HLA Mismatches) was to develop a tool to compare the chance of transplanting HSP in different European populations with donor organs from within and outside their own donor pool. Information on the HLA type and ABO blood group of the actual donor population, as well as the acceptable mismatches of long waiting HSP were obtained from the EUROSTAM partner organizations i.e. Eurotransplant (ET), UK National Health Service Blood and Transplant (NHSBT), Barcelona, Prague and Athens. Results from simulations using the newly developed tool shows that 195 (27%) of the 724 long waiting highly sensitised patients registered at each partner organisation have increased chances of transplant in a different European donor pool. This makes a strong case for sharing kidneys between European countries for selected difficult to transplant patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prueba de Histocompatibilidad / Trasplante de Riñón / Antígenos HLA Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Transpl Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA / TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prueba de Histocompatibilidad / Trasplante de Riñón / Antígenos HLA Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Transpl Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA / TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido